Company intelligence / Profile preview

Akaza Bioscience Ltd.

Northampton, United Kingdomventureradar.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Akaza Bioscience is a UK-based private biotech company developing immunological therapies for severe liver diseases. Its lead asset, TAK-242, is a small molecule TLR4 inhibitor currently in Phase 2 trials for acute alcoholic hepatitis and acute-on-chronic liver failure. Clinical results are not yet publicly available; the most recent trial status is "unknown" or "not yet recruiting" as of early 2025[2][10].

Therapeutic areas: Gastroenterology
Modalities: Small molecules (notably TAK-242/Resatorvid)[2][10]
Industry: Biotech

Drug pipeline

1 asset

resatorvid

Phase 2

Indications: Acute-on-Chronic Liver Failure (ACLF)

Beyond the preview

Go deeper on Akaza Bioscience Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akaza Bioscience Ltd..

Explore the full profile